How can we use biologics and surgery to get the best outcomes for patients with CRSwNP?

The management of patients with Chronic Rhinosinusitis with Nasal Polyps (or CRSwNP) has been subject to a major revolution of care, considering the improved knowledge of the underlying pathology over the past two decades, the recommendation to evaluate biomarkers with the indication of biologics, and the increased awareness of comorbidities.

For several years, biologics have been indicated and available in a growing number of countries for severe uncontrolled CRSwNP. However, surgery (or even revision surgery) remains the most widely used option in most countries around the world. 

This debate aims to explore the main therapeutic options and to address the main question: How can we use biologics and surgery to achieve the best outcomes for patients with CRSwNP?

Panellists:

• Prof. Wytske Fokkens
• Prof. Adam Chaker
• Prof. Joseph Han
• Prof. Joaquim Mullol
• Ms. Daisy Waeyenbergh
• Ms. Natascha Siemes